[1]
|
韦慧萍, 兰访, 朱璇, 李山. 相关实验室检查指标与多发性骨髓瘤合并肾损害的关系研究[J]. 广西医科大学学报, 2016, 33(6): 996-999.
|
[2]
|
Sathick, I.J., Drosou, M.E. and Leung, N. (2019) Myeloma Light Chain Cast Nephrop-athy, a Review. Journal of Nephrology, 32, 189-198. https://doi.org/10.1007/s40620-018-0492-4
|
[3]
|
刘萌萌, 许洪志, 冯秀梅, 张越, 刘言训. 多发性骨髓瘤肾损害危险因素及其可逆性预测指标的临床相关研究[J]. 中国实验血液学杂志, 2015. 23(3): 722-727.
|
[4]
|
Dejoie, T., et al. (2016) Serum Free Light Chains, Not Urine Specimens, Should Be Used to Evaluate Response in Light-Chain Multiple Myeloma. Blood, 128, 2941-2948. https://doi.org/10.1182/blood-2016-07-726778
|
[5]
|
Dejoie, T., et al. (2019) Responses in Multiple Myeloma Should Be Assigned According to Serum, Not Urine, Free Light Chain Measurements. Leukemia, 33, 313-318. https://doi.org/10.1038/s41375-018-0339-y
|
[6]
|
罗添丞, 卢静, 强婉婷, 傅卫军, 杜鹃. 单克隆免疫球蛋白病合并神经功能异常1例及文献复习[J]. 临床荟萃, 2019, 34(4): 352-355.
|
[7]
|
Dimopoulos, M.A., et al. (2016) In-ternational Myeloma Working Group Recommendations for the Diagnosis and Management of Myeloma-Related Renal Impairment. Journal of Clinical Oncology, 34, 1544-1557.
https://doi.org/10.1200/JCO.2015.65.0044
|
[8]
|
Andronesi, A.G., et al. (2019) Incidence and Risk Factors for Acute Kidney Injury Following Autologous Stem Cell Transplantation for Multiple Myeloma. Cancer Medicine, 8, 3278-3285. https://doi.org/10.1002/cam4.2187
|
[9]
|
Stokes, M.B., et al. (2016) Light Chain Proximal Tubulopathy: Clinical and Pathologic Characteristics in the Modern Treatment Era. Journal of the American Society of Nephrology, 27, 1555-1565.
https://doi.org/10.1681/ASN.2015020185
|
[10]
|
Rysava, R. (2020) Renal Failure in Multiple Myeloma and Its Treatment. Vnitrní Lékarství, 66, 425-431.
https://doi.org/10.36290/vnl.2020.122
|
[11]
|
Martellosio, J.P., et al. (2019) Free Light Chains Assay: Indications and Methods. La Revue de Médecine Interne, 40, 297-305. https://doi.org/10.1016/j.revmed.2019.01.005
|
[12]
|
Rajkumar, S.V. (2020) Multiple Myeloma: 2020 Update on Di-agnosis, Risk-Stratification and Management. American Journal of Hematology, 95, 548-567. https://doi.org/10.1002/ajh.25791
|
[13]
|
Gertz, M.A. (2020) Immunoglobulin Light Chain Amyloidosis: 2020 Up-date on Diagnosis, Prognosis, and Treatment. American Journal of Hematology, 95, 848-860. https://doi.org/10.1002/ajh.25819
|
[14]
|
Handa, H., et al. (2019) The Role and Function of MicroRNA in the Patho-genesis of Multiple Myeloma. Cancers, 11, Article No. 1738. https://doi.org/10.3390/cancers11111738
|
[15]
|
Wang, J.H., et al. (2016) Expression and Significance of miR-21 in Multiple Myeloma Patients. Genetics and Molecular Re-search, 15, gmr.15016892. https://doi.org/10.4238/gmr.15016892
|
[16]
|
Wu, H., et al. (2020) MIR145-3p Promotes Autophagy and Enhances Bortezomib Sensitivity in Multiple Myeloma by Targeting HDAC4. Autophagy, 16, 683-697. https://doi.org/10.1080/15548627.2019.1635380
|
[17]
|
Manier, S., Liu, C.-J., et al. (2017) Prognostic Role of Cir-culating Exosomal miRNAs in Multiple Myeloma. Blood, 129, 2429-2436. https://doi.org/10.1182/blood-2016-09-742296
|
[18]
|
Ma, Z., et al. (2018) Dicer Deficiency in Proximal Tubules Exacerbates Renal Injury and Tubulointerstitial Fibrosis and Upregulates Smad2/3. American Journal of Physiology, 315, F1822-F1832.
https://doi.org/10.1152/ajprenal.00402.2018
|
[19]
|
Vinas, J.L., et al. (2021) Micro-RNA-486-5p Protects against Kidney Ischemic Injury and Modifies the Apoptotic Transcriptome in Proximal Tubules. Kidney International, 100, 597-612. https://doi.org/10.1016/j.kint.2021.05.034
|
[20]
|
Lorenzen, J.M., et al. (2014) MicroRNA-24 Antagonism Prevents Renal Ischemia Reperfusion Injury. Journal of the American Society of Nephrology 25, 2717-2729. https://doi.org/10.1681/ASN.2013121329
|
[21]
|
Cardenas-Gonzalez, M., et al. (2017) Identification, Confirmation, and Replication of Novel Urinary MicroRNA Biomarkers in Lupus Nephritis and Diabetic Nephropathy. Clinical Chem-istry, 63, 1515-1526.
https://doi.org/10.1373/clinchem.2017.274175
|
[22]
|
Pavkovic, M. and Vaidya, V.S. (2016) MicroRNAs and Drug-Induced Kidney Injury. Pharmacology & Therapeutics, 163, 48-57. https://doi.org/10.1016/j.pharmthera.2016.03.016
|
[23]
|
Kolling, M., et al. (2017) Therapeutic miR-21 Silencing Ameliorates Diabetic Kidney Disease in Mice. Molecular Therapy, 25, 165-180. https://doi.org/10.1016/j.ymthe.2016.08.001
|
[24]
|
Papanota, A.M., et al. (2021) A Molecular Signature of Circulat-ing MicroRNA Can Predict Osteolytic Bone Disease in Multiple Myeloma. Cancers, 13, Article No. 3877. https://doi.org/10.3390/cancers13153877
|
[25]
|
Mosquera, O.A., et al. (2021) Survival Prediction and Treatment Optimization of Multiple Myeloma Patients Using Machine-Learning Models Based on Clinical and Gene Expression Data. Leukemia, 35, 2924-2935.
https://doi.org/10.1038/s41375-021-01286-2
|
[26]
|
胥兴丽, 原江水, 王仁峰. Cys-C、β2-M及轻链类型检测在多发性骨髓瘤肾损伤诊断中的应用[J]. 检验医学与临床, 2020, 17(23): 3414-3416.
|
[27]
|
宋斌, 陈雁, 张荣耀, 李娜, 耿伟, 郭秀, 等. 血清CysC、Cr及LDH水平变化诊断多发性骨髓瘤早期肾损伤的价值[J]. 现代肿瘤医学, 2018, 26(21): 3471-3474.
|
[28]
|
Zhang, J., et al. (2022) The Role of Cystatin C in Multiple Myeloma. International Journal of Laboratory Hematologyl, 44, 135-141. https://doi.org/10.1111/ijlh.13695
|
[29]
|
Li, R., et al. (2021) Cystatin C Level Is Associated with the Recovery of Renal Function in Cancer Patients after Onset of Acute Kidney Injury. Annals of Pal-liative Medicine, 10, 2158-2166. https://doi.org/10.21037/apm-21-191
|
[30]
|
Guo, S., et al. (2017) Preoperative Se-rum Cystatin-C as a Potential Biomarker for Prognosis of Renal Cell Carcinoma. PLoS ONE, 12, Article ID: e0178823. https://doi.org/10.1371/journal.pone.0178823
|
[31]
|
Choudhary, A., et al. (2018) Association and Prognostic Value of Serum Cystatin C, IL-18 and Uric Acid in Urological Patients with Acute Kidney Injury. Clinica Chimica Acta, 482, 144-148. https://doi.org/10.1016/j.cca.2018.04.005
|
[32]
|
Kumar, S.K., et al. (2017) Multiple Myeloma. Nature Re-views Disease Primers, 3, Article No. 17046.
https://doi.org/10.1038/nrdp.2017.46
|
[33]
|
Łacina, P., et al. (2021) Association of RANK and RANKL Gene Pol-ymorphism with Survival and Calcium Levels in Multiple Myeloma. Molecular Carcinogenesis, 60, 106-112. https://doi.org/10.1002/mc.23272
|
[34]
|
Beider, K., et al. (2020) Blocking of Transient Receptor Potential Vanilloid 1 (TRPV1) Promotes Terminal Mitophagy in Multiple Myeloma, Disturbing Calcium Homeostasis and Targeting Ubiquitin Pathway and Bortezomib-Induced Unfolded Protein Response. Journal of Hematology & Oncology, 13, Article No.158.
https://doi.org/10.1186/s13045-020-00993-0
|
[35]
|
王岩, 黄仲夏, 胡婉莉, 魏宇君, 王林月. 血管细胞黏附分子-1和激活素A对多发性骨髓瘤的影响研究[J]. 中国全科医学, 2021, 24(17): 2185-2191.
|
[36]
|
Bian, X., et al. (2019) Senescence Marker Activin A Is Increased in Human Diabetic Kidney Disease: Association with Kidney Function and Potential Implications for Therapy. BMJ Open Diabetes Research & Care, 7, Article ID: e000720.
https://doi.org/10.1136/bmjdrc-2019-000720
|
[37]
|
Iriuchishima, H., et al. (2019) Activin A: A Novel Urinary Bi-omarker of Renal Impairment in Multiple Myeloma. Bioscience Reports, 39, Article ID: BSR20190206. https://doi.org/10.1042/BSR20190206
|
[38]
|
Feng, Z., et al. (2020) Reduced Expression of Proteolipid Protein 2 In-creases ER Stress-Induced Apoptosis and Autophagy in Glioblastoma. Journal of Cellular and Molecular Medicine, 24, 2847-2856.
https://doi.org/10.1111/jcmm.14840
|
[39]
|
Xiao, W., et al. (2020) MiR-765 Functions as a Tumour Suppressor and Eliminates Lipids in Clear Cell Renal Cell Carcinoma by Downregulating PLP2. eBioMedicine, 51, Article ID: 102622.
https://doi.org/10.1016/j.ebiom.2019.102622
|
[40]
|
Bai, H., et al. (2020) PLP2 Expression as a Prognostic and Therapeutic Indicator in High-Risk Multiple Myeloma. BioMed Research International, 2020, Article ID: 4286101. https://doi.org/10.1155/2020/4286101
|
[41]
|
Chen, Y., Hueng, D. and Tsai, W. (2018) Proteolipid Protein 2 Over-expression Indicates Aggressive Tumor Behavior and Adverse Prognosis in Human Gliomas. International Journal of Molecular Sciences, 19, Article No. 3353.
https://doi.org/10.3390/ijms19113353
|
[42]
|
Hussain, A., et al. (2019) Laboratory Features of Newly Diagnosed Multiple Myeloma Patients. Cureus, 11, Article No. e4716. https://doi.org/10.7759/cureus.4716
|
[43]
|
张冠男, 戈伟. 血清肿瘤标志物糖类抗原CA125在原发性胃弥漫大B淋巴瘤中的临床意义[J]. 中国医药导报, 2016, 13(26): 88-91.
|